Synonym
Pyrazinobutazone; Carudol; DB 139; DB-139; DB139; Ranoroc;
IUPAC/Chemical Name
4-butyl-1,2-diphenylpyrazolidine-3,5-dione compound with piperazine (1:1)
InChi Key
HWGAOXKGTHUMFZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H20N2O2.C4H10N2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;1-2-6-4-3-5-1/h4-13,17H,2-3,14H2,1H3;5-6H,1-4H2
SMILES Code
CCCCC1C(N(c2ccccc2)N(c3ccccc3)C1=O)=O.C4CNCCN4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
394.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Maria VA, da Silva JA, Victorino RM. Agranulocytosis and liver damage associated with pyrazinobutazone with evidence for an immunological mechanism. J Rheumatol. 1989 Nov;16(11):1484-5. PubMed PMID: 2600947.
2: Dorado Bris JM, Aragues Montañes M, Sols Candela M, Garcia Diez A. Contact sensitivity to pyrazinobutazone (Carudol) with positive oral provocation test. Contact Dermatitis. 1992 May;26(5):355-6. PubMed PMID: 1395605.
3: Nove-Josserand G, Philippe LP, Ortonne JP, Gaillarde B, Pugiat M, Plauchu M. [Value of pyrazinobutazone in the treatment of various inflammatory conditions]. Lyon Med. 1972 Mar 26;227(6):587-90. French. PubMed PMID: 4538275.
4: Gaillarde B, Ortonne JP, Pugeat M, Plauchu M. [Value of pyrazinobutazone in the treatment of different inflammatory states]. J Med Lyon. 1972 Oct 5;53(234):1315-6 passim. French. PubMed PMID: 4539046.
5: Fournie A, Ayrolles C. [Pyrazinobutazone in rheumatology (Clinical study of 50 cases)]. Rhumatologie. 1972 Aug-Sep;24(7):287-91. French. PubMed PMID: 4540383.
6: Giroud MM, Maccotta. [Personal experimentation with pyrazinobutazone in dentistry]. Inf Dent. 1973 Mar 29;55(13):29-31. French. PubMed PMID: 4515315.
7: Commissionat Y, Daieff CY. [Pyrazinobutazone its activity in stomatology]. Rev Odontostomatol (Paris). 1973 Jan-Feb;20(1):77-8. French. PubMed PMID: 4516776.
8: Naudy F. [Value of pyrazinobutazone in long term treatment of chronic pain syndromes in the aged]. Therapeutique. 1973 May-Jun;49(5):379-83. French. PubMed PMID: 4205634.
9: von Bruchhausen V, Lohmann H, O'sváth J. The pharmacokinetic profile of pyrazinobutazone in man. Arzneimittelforschung. 1978;28(12):2337-43. PubMed PMID: 582952.
10: Toussaint J, Vermeire M. [Diffractometric study of pyrazinobutazone and related compounds]. Ann Pharm Fr. 1974 Jun;32(6):383-90. French. PubMed PMID: 4433140.
11: Le Chevallier PL. [The anti-inflammatory clinical effects of pyrazinobutazone (study of 44 cases with principally rheumatologic indications)]. Rhumatologie. 1972 Mar;24(3):91-100. French. PubMed PMID: 4538813.
12: Nicolas P. [Pyrazinobutazone in conservative dentistry]. Chir Dent Fr. 1971 Dec 8;41(93):61-2. French. PubMed PMID: 5291811.
13: Delhaye JP, Famaey JP. [Clinical evaluation in 42 rheumatic patients of a new pyrazole derivative: pyrazinobutazone or Carudol]. J Dent Assoc S Afr. 1973 Jan-Feb;28(1):14-22. French. PubMed PMID: 4542571.
14: Herzer P, Lemmel EM. Inhibition of granulocyte function by prednisolone and non-steroid anti-inflammatory drugs. Quantitative evaluation with NBT test and its correlation with phagocytosis. Immunobiology. 1980 Apr;157(1):78-88. PubMed PMID: 6894133.
15: Alessandrini A, Gemini R. [Comparative clinical study of the efficacy of and tolerance for lysine para-isobutylphenyl propionate in parallel with indomethacin and pyrasanone]. Clin Ter. 1980 Jul 31;94(2):137-47. Italian. PubMed PMID: 6450020.
16: Bantz W. [Ranoroc in the treatment of degenerative joint and spinal diseases]. Med Welt. 1980 Nov 7;31(45):1636-8. German. PubMed PMID: 6893852.
17: Kafarnik D, Semmler U, Pfannenstiel P, Miehlke K. [Comparative drug therapy study with scintigraphic control research]. Z Rheumatol. 1981 Mar-Apr;40(2):62-5. German. PubMed PMID: 6895140.
18: Baldi C, D'Ajello M, Balbi GC. [Treatment of dysmenorrhea with Pyrasanone]. Minerva Ginecol. 1983 Apr;35(4):247-50. Italian. PubMed PMID: 6350940.
19: Batko B. [Phenylbutazone derivatives and duodenal extrabulbar ulcer]. Wiad Lek. 1979 Dec 1;32(23):1707-10. Polish. PubMed PMID: 583380.
